The second-most common breast cancer subtype may finally have a targeted treatment pathway, addressing a critical gap for patients facing particularly poor long-term survival rates. Invasive lobular carcinoma accounts for 10-15% of breast cancers but has long puzzled oncologists with its resistance to standard hormone therapies despite appearing hormone-sensitive.
Researchers discovered that lobular breast cancer cells exhibit a distinctive form of DNA repair dysfunction centered on altered interactions between estrogen receptor and MDC1, a key DNA damage checkpoint protein. Unlike BRCA-mutated cancers that completely lose homologous recombination repair, lobular tumors maintain partial function but operate in a compromised "BRCA-like" state. Single-cell analysis revealed these cells struggle to properly initiate and execute DNA repair processes, creating vulnerability without the characteristic genomic scarring patterns seen in classic BRCA deficiency.
This finding carries significant therapeutic implications given that lobular breast cancer patients experience higher recurrence rates than other hormone-positive breast cancers, suggesting current endocrine therapies fail to address the underlying biology. The research team demonstrated that talazoparib, an FDA-approved PARP inhibitor currently used for BRCA-mutated cancers, produced sustained tumor suppression in multiple lobular cancer models. The mechanism appears fundamentally different from existing PARP inhibitor applications, potentially expanding treatment options for thousands of women annually. However, the study's reliance on laboratory models means clinical validation through human trials remains essential before changing treatment protocols for this historically challenging cancer subtype.